{
    "clinical_study": {
        "@rank": "60491", 
        "arm_group": [
            {
                "arm_group_label": "Tiotropium/Olodaterol FDC", 
                "arm_group_type": "Experimental", 
                "description": "patient will receive tiotropium and olodaterol in a fixed dose combination"
            }, 
            {
                "arm_group_label": "Tiotropium and Olodaterol FC", 
                "arm_group_type": "Experimental", 
                "description": "patient will receive tiotropium and olodaterol in a free combination"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "patient will receive placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of this study is to evaluate the efficacy and safety of orally inhaled\n      tiotropium and olodaterol as both a fixed dose combination and a free combination with\n      respect to lung function and ECG parameters"
        }, 
        "brief_title": "Study to Evaluate the Effect on Lung Function and ECG When a Combination of Tiotropium Plus Olodaterol is Administered to Patients With COPD Either From a Single Inhaler or Each Compound is Administered After Each Other From Two Different Inhalers", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Pulmonary Disease, Chronic Obstructive", 
        "condition_browse": {
            "mesh_term": [
                "Chronic Disease", 
                "Lung Diseases", 
                "Respiration Disorders", 
                "Pulmonary Disease, Chronic Obstructive", 
                "Lung Diseases, Obstructive"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  patients must sign informed consent consistent with ICH-GCP guidelines prior to\n             participation in the trial, which includes medication washout and restrictions.\n\n          -  Patients must have a diagnosis of COPD and must meet the following spirometric\n             criteria:\n\n        Patients must have relatively stable airway obstruction with a post-bronchodilator (10 to\n        45 minutes after 400mcg salbutamol) FEV1>30% and < 80% of predicted normal (ECSC, GOLD II\n        - III)  and a post-bronchodilator FEV1/FVC <70% at Visit 1\n\n          -  Male or female patients, 40 years of age or older.\n\n          -  Patients must be current or ex-smokers with a smoking history of more than 10 pack\n             years.\n\n          -  Patients who have never smoked cigarettes must be excluded.\n\n          -  Patients must be able to perform technically acceptable pulmonary function tests\n             according to ATS/ERS guidelines and maintain records in a paper diary\n\n          -  Patients must be able to inhale medication in a competent manner from the RESPIMAT\n             inhaler and from a metered dose inhaler (MDI).\n\n        Exclusion criteria:\n\n          -  Significant disease other than COPD\n\n          -  Clinically relevant abnormal lab values.\n\n          -  History of asthma.\n\n          -  Diagnosis of thyrotoxicosis\n\n          -  Diagnosis of paroxysmal tachycardia\n\n          -  History of myocardial infarction within 1 year of screening visit\n\n          -  Unstable or life-threatening cardiac arrhythmia\n\n          -  Hospitalization for heart failure within the past year\n\n          -  Known active tuberculosis\n\n          -  Malignancy for which patient has undergone resection, radiation therapy or\n             chemotherapy within last five years\n\n          -  History of life-threatening pulmonary obstruction and patients with chronic\n             respiratory failure\n\n          -  History of cystic fibrosis\n\n          -  Clinically evident bronchiectasis\n\n          -  History of significant alcohol or drug abuse\n\n          -  Thoracotomy with pulmonary resection\n\n          -  Patients treated with oral or patch \u00df-adrenergics\n\n          -  Patients treated with oral corticosteroid medication at unstable doses or at doses in\n             excess of 10mg prednisolone per day or equivalent\n\n          -  Regular use of daytime oxygen therapy for more than one hour per day\n\n          -  Pulmonary rehabilitation program in the six weeks prior to the screening visit or\n             patients currently in a pulmonary rehabilitation program\n\n          -  Investigational drug within one month or six half lives (whichever is greater) prior\n             to screening visit\n\n          -  Known hypersensitivity to \u00df-adrenergic and/or anticholinergic drugs, BAC, EDTA\n\n          -  Pregnant or nursing women\n\n          -  Women of childbearing potential not using a highly effective method of birth control\n\n          -  Patient who have previously been randomized in this study or are currently\n             participating in another study\n\n          -  Patients who are unable to comply with pulmonary medication restrictions prior to\n             randomization"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "53", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 7, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02030535", 
            "org_study_id": "1237.7", 
            "secondary_id": "2013-002652-32"
        }, 
        "intervention": [
            {
                "arm_group_label": "Tiotropium and Olodaterol FC", 
                "description": "free combination with tiotropium", 
                "intervention_name": "olodaterol", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Tiotropium and Olodaterol FC", 
                "description": "free combination with olodaterol", 
                "intervention_name": "tiotropium", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Tiotropium/Olodaterol FDC", 
                "description": "fixed dose combination with olodaterol", 
                "intervention_name": "tiotropium", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Tiotropium/Olodaterol FDC", 
                "description": "fixed dose combination with tiotropium", 
                "intervention_name": "olodaterol", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Tiotropium"
        }, 
        "lastchanged_date": "May 28, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany"
                    }, 
                    "name": "1237.7.49005 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany"
                    }, 
                    "name": "1237.7.49004 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Frankfurt", 
                        "country": "Germany"
                    }, 
                    "name": "1237.7.49007 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gro\u00dfhansdorf", 
                        "country": "Germany"
                    }, 
                    "name": "1237.7.49002 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hamburg", 
                        "country": "Germany"
                    }, 
                    "name": "1237.7.49003 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Weinheim", 
                        "country": "Germany"
                    }, 
                    "name": "1237.7.49001 Boehringer Ingelheim Investigational Site"
                }
            }
        ], 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomised, Placebo-controlled, Double-blind, Single Dose, Cross-over Study to Evaluate the Efficacy and Safety of Orally Inhaled Tiotropium + Olodaterol as Both a Fixed Dose Combination and a Free Combination (Both Delivered by the Respimat\u00ae Inhaler) in Patients With Chronic Obstructive Pulmonary Disease (COPD)", 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "United States: Food and Drug Administration"
            ]
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "FEV1 AUC0-3h response (Response is defined as the change from patient baseline, patient baseline is the average of the mean pre-dose values on each test day)", 
            "safety_issue": "No", 
            "time_frame": "3 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02030535"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Mean QTcF interval change from patient baseline over all post-dose time points (5min, 10min, 25min and 50min)", 
                "safety_issue": "No", 
                "time_frame": "3 hours"
            }, 
            {
                "measure": "Peak QTcF interval change from patient baseline over all post-dose time points (5min, 10min, 25min and 50min)", 
                "safety_issue": "No", 
                "time_frame": "3 hours"
            }, 
            {
                "measure": "Mean heart rate change from patient baseline over all post-dose time points (5min, 10min, 25min and 50min)", 
                "safety_issue": "No", 
                "time_frame": "3 hours"
            }, 
            {
                "measure": "Peak heart rate change from patient baseline over all post-dose time points (5min, 10min, 25min and 50min)", 
                "safety_issue": "No", 
                "time_frame": "3 hours"
            }
        ], 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}